Feb 4, 2026 04:05PM
Dec 18, 2025 07:30AM
Dec 18, 2025 07:30AM
Dec 10, 2025 07:30AM
Dec 10, 2025 07:30AM
Dec 1, 2025 07:30AM
Dec 1, 2025 07:30AM ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Dec 1, 2025 07:00AM
Nov 12, 2025 07:00AM
Nov 12, 2025 07:00AM
Nov 3, 2025 04:05PM
Oct 22, 2025 07:31AM
Oct 22, 2025 07:30AM
Sep 3, 2025 07:00AM ProMIS Neurosciences advances to final dose cohort in alzheimer's trial
Sep 3, 2025 07:00AM
Aug 13, 2025 07:00AM
Aug 13, 2025 07:00AM
Jul 29, 2025 08:00AM
Jul 29, 2025 08:00AM
Jul 22, 2025 06:40AM
Jul 21, 2025 08:04AM ProMIS Neurosciences receives FDA fast track status for Alzheimer's drug
Jul 21, 2025 08:00AM
Nov 14, 2023 04:30PM
Aug 14, 2023 05:33PM
Jul 17, 2023 07:00AM
May 15, 2023 05:00PM
May 8, 2023 09:00AM
May 8, 2023 09:00AM ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
Apr 10, 2023 07:30AM
Apr 10, 2023 07:30AM
Apr 10, 2023 07:30AM
Mar 29, 2023 08:31AM
Mar 29, 2023 08:30AM
Mar 29, 2023 08:30AM
Mar 8, 2023 05:06PM ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
Mar 8, 2023 05:06PM
Nov 14, 2022 07:00AM
Nov 14, 2022 07:00AM
Oct 12, 2022 07:00AM
Oct 12, 2022 07:00AM
Sep 13, 2022 07:00AM
Sep 13, 2022 07:00AM ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer
Aug 15, 2022 05:00PM
Aug 15, 2022 05:00PM
Jun 22, 2022 07:00AM
Apr 18, 2022 09:05AM
Nov 12, 2021 07:00AM
Oct 22, 2021 07:00AM
Aug 4, 2021 07:30AM ProMIS Neurosciences Issues Chairman’s Memorandum
Jun 8, 2021 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All